Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

MBX Biosciences (MBX) EBIT (2023 - 2026)

MBX Biosciences has reported EBIT over the past 4 years, most recently at -$27.3 million for Q1 2026.

  • Quarterly results put EBIT at -$27.3 million for Q1 2026, down 2.77% from a year ago — trailing twelve months through Mar 2026 was -$98.8 million (down 21.35% YoY), and the annual figure for FY2025 was -$98.1 million, down 43.79%.
  • EBIT reached -$27.3 million in Q1 2026 per MBX's latest filing, down from -$25.8 million in the prior quarter.
  • Across five years, EBIT topped out at -$10.0 million in Q4 2023 and bottomed at -$27.3 million in Q1 2026.
  • Median EBIT over the past 4 years was -$19.6 million (2024), compared with a mean of -$19.5 million.
  • The largest annual shift saw EBIT plummeted 99.26% in 2025 before it fell 2.77% in 2026.
  • Over 4 years, EBIT stood at -$10.0 million in 2023, then tumbled by 86.27% to -$18.6 million in 2024, then plummeted by 38.61% to -$25.8 million in 2025, then fell by 5.7% to -$27.3 million in 2026.
  • Business Quant data shows EBIT for MBX at -$27.3 million in Q1 2026, -$25.8 million in Q4 2025, and -$23.9 million in Q3 2025.